[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356093-105":59,"doc-detail-356093-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","sensitive-car-t-cells-redefine-targetable-cd70-expression-in-solid-tumors","Sensitive CAR T cells redefine targetable CD70 expression in solid tumors","","Chimeric antigen receptor (CAR) T cell therapies effectively treat hematological malignancies but fail in solid tumors due to heterogeneous target antigen expression across tumor cell populations. The study focuses on CD70 as a potentially ideal target, noting that conventional detection often shows heterogeneous CD70 presence in solid tumors. The authors hypothesize that CD70 may be expressed on all tumor cells at levels below conventional detection and CAR T sensitivity, and that a more sensitive CAR receptor could eliminate tumors more completely. The work develops CD70-heterogeneous tumor models for mechanistic investigation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sensitive-car-t-cells-redefine-targetable-cd70-expression-in-solid-tumors/356093/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sensitive-car-t-cells-redefine-targetable-cd70-expression-in-solid-tumors/356093.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why do CAR T cells fail in solid tumors compared with blood cancers?","Question",{"text":113,"@type":114},"Because target antigen expression is inconsistent across tumor cells in solid tumors, leading to incomplete elimination and disease progression.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What makes CD70 a candidate target for CAR T therapy in solid tumors?",{"text":118,"@type":114},"CD70 potentially fits criteria for restricted expression on dispensable normal cells and relevance across many tumor types, though its expression appears heterogeneous with conventional detection.",{"name":120,"@type":111,"acceptedAnswer":121},"What hypothesis does the study test about CD70-negative tumor cells?",{"text":122,"@type":114},"Tumor cells that seem CD70-negative may express CD70 at very low levels undetectable by conventional methods and CAR T cells; a more sensitive receptor could eliminate all tumor cells.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356093,1790686151,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Science. Author manuscript; available in PMC 2026 August 20. |\n| --- | --- |\n\nPublished in final edited form as:  \nScience. 2026 February 26; 391(6788): 896–905. doi:10.1126/science.adv7378 .  \nSensitive CAR T cells redefine targetable CD70 expression in solid tumors  \nSophie A. Hanina 1 , Tyler Park2,†, Michael Lopez 1,†, Vinagolu K. Rajasekhar3,†, Jorge Mansilla-Soto4,‡, Sascha Haubner1 , Huiyong Zhao5 , Friederike Kogel4 , Sarah Nataraj 1 , Priyam Banerjee6 , Richard Koche7 , Pierre-Jacques Hamard7 , Zeynep C. Tarcan8 , Dennis  \nS. Chi9,10 , Dmitriy Zamarin 11 , John H. Healey3 , Elisa de Stanchina5 , Robert J. Motzer12 , Ritesh R. Kotecha 12 , A. Ari Hakimi 13,14 , Christina S. Leslie2 , Michel Sadelain 1,*  \n1Columbia Initiative in Cell Engineering and Therapy (CICET), Department of Medicine, Columbia University Irving Medical Center, Columbia University, New York, NY USA.  \n2Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n3Orthopedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n4Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n5Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n6Bio-Imaging Resource Center, The Rockefeller University, New York, NY USA.  \n7Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n8 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \n9Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.  \nLicense information: Copyright © 2026 the authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original US government works. [https://www.sciencemag.org/about/science-licenses-journal](https://www.sciencemag.org/about/science-licenses-journal)article-reuse.  \n*C†Torhessepandthngrsacthorntrib:uMictedelquSalaldyetinthimwwos2rk[1](188@cumc.columbia.edu)[88@cumc.columbia.edu](188@cumc.columbia.edu)).  \n‡Present address: Departments of Immunology, Bioengineering, and Blood & Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.  \nAuthor contributions: Conceptualization: S.A.H., M.S. Methodology: S.A.H., J.M.-S., S.H., P.B., P.-J.H., V.K.R. Investigation:  \nS.A.H., H.Z., F.K., S.N., P.B. Formal analysis: T.P., M.L., R.Ko., C.S,L. Resources: V.K.R., D.S.C., D.Z., J.H.H., E.d.S., A.A.H. Visualization: S.A.H. Funding acquisition: S.A.H., R.J.M., M.S. Writing– original draft: S.A.H., M.S. Writing – review & editing:  \nS.A.H., T.P., M.L., P.J.H., R.R.K., C. S.L., M. S.  \nCompeting interests: Memorial Sloan Kettering has submitted a patent application based in part on results presented in this manuscript (S.A.H. and M.S. are listed among the inventors) . J.M.-S. and M.S. are listed as coinventors on a patent related to the HIT platform (WO2019157454A1) . R.Ko. is a cofounder of and consultant for Econic Biosciences. D.S.C. reports membership of the medical advisory board of Verthermia Acquio and Biom’Up; is a paid speaker for AstraZeneca; holds stock in Doximity and BioNTech SE; and receives royalties from McGraw Hill, Taylor and Francis, and Wolters Kluwer. R.J.M. has provided consulting or advisory roles for Merck and has received research funding from Aveo, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Novartis, Pfizer, and Merck. R.R.K. reports consulting or advisory role for Eisai and institutional research funding from Pfizer, Takeda, Novartis, Allogene Therapeutics, Exelixis, ArsenalBio, and Xencor. C.S.L. is a scientific advisory board member and coinventor of intellectual property with Episteme Prognostics, unrelated to th","cbCairVihmlaA3W7","https://ap.wps.com/l/cbCairVihmlaA3W7","pdf",2690873,26,"English","# Abstract\n## Introduction\n## Rationale\n## Results","[{\"question\":\"Why do CAR T cells fail in solid tumors compared with blood cancers?\",\"answer\":\"Because target antigen expression is inconsistent across tumor cells in solid tumors, leading to incomplete elimination and disease progression.\"},{\"question\":\"What makes CD70 a candidate target for CAR T therapy in solid tumors?\",\"answer\":\"CD70 potentially fits criteria for restricted expression on dispensable normal cells and relevance across many tumor types, though its expression appears heterogeneous with conventional detection.\"},{\"question\":\"What hypothesis does the study test about CD70-negative tumor cells?\",\"answer\":\"Tumor cells that seem CD70-negative may express CD70 at very low levels undetectable by conventional methods and CAR T cells; a more sensitive receptor could eliminate all tumor cells.\"}]","Sensitive CAR T cells redefine targetable CD70 expression in solid tumors | PDF",1790123367,66,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0e7fe9479d0fef0d753dfd4e3bc06d8.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b050bd6c5494ff56dbff690ba20d4d95.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef6048a761d8ccdc82f60a666a98d983.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db0d385467ba437e9f39bf2adbc7ce21.webp",980,1268]